What is the role of medications in the treatment of Acinetobacter infection?

Updated: Mar 02, 2021
  • Author: Shirin A Mazumder, MD, FIDSA; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print

Owing to the propensity of Acinetobacter to develop resistance to antibiotics, current treatment strategies remain limited. Beta-lactam antibiotics are the preferred antibacterial choices for susceptible A baumannii infections. Because of increasing resistance, carbapenems have become an increasingly critical therapeutic option for Acinetobacter infections; however, carbapenem resistance rates for A baumannii have been rising dramatically, both in the United States and globally. [1] Minocycline may retain antimicrobial activity even against strains resistant to other tetracyclines (including tigecycline), although cross-resistance has been reported. [1] In cases of nonbacteremic drug-resistant Acinetobacter pneumonia, the addition of inhaled colistin can be considered. This approach may minimize toxicity and increase antibiotic delivery to the lung. [1]

A baumannii is intrinsically multidrug resistant. Relatively few antibiotics are active against this organism. [6, 7, 8] Avoid treating colonization, but infection should be treated.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!